

a3 10. (Amended) The recombinant avian herpesvirus designated NAHV 295-01 (ATCC Accession number PTA-3451).

a4 17. (Amended) A multivalent vaccine for protecting against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising, as a mixture, an effective immunizing amount of a first recombinant avian herpesvirus, designated NAHV/ILT 295-149 (ATCC Accession number PTA-3452), an effective immunizing amount of a second recombinant avian herpesvirus, designated NAHV/NDV 295-93 (ATCC Accession number PTA-3453), and a suitable carrier.

IN THE SPECIFICATION

Please amend the specification as follows:

On Page 19, line 11 to page 19, line 22 substitute the present pending paragraph with the following paragraph:

a5 --The dC-tailed DNA sample was annealed to 200 ng plasmid vector pBR322 that contained oligo-dG tails (Bethesda Research Labs #5355 SA/SB) in 200 μ l of 0.01 M Tris pH 7.5, 0.1 M NaCl, 1 mM EDTA pH 8.0 at 65°C for 2 min and then 57°C for 2 hrs. Fresh competent *E. coli* DH-1 cells were prepared and transformed as described by Hanahan (*Molecular Biology* 166, 557-580, 1983) using half the annealed cDNA sample in twenty 200 μ l aliquots of cells. Transformed cells were plated on L-broth agar plates plus 10 μ g/ml tetracycline. Colonies were screened for the presence of inserts into the ampicillin gene using Ampscreen (Bethesda Research Labs #5537 UA), and the positive colonies were picked for analysis. Resulting positive clones were screened for homology to paramyxovirus fusion gene sequences. A clone containing the complete coding